European Society for Medical Oncology Congress

The addition of lorazepam to haloperidol reduced symptoms of agitated delirium among individuals with advanced cancers, according to study findings.

Researchers reported beneficial effects of a supervised exercise intervention on breast cancer outcomes, according to preliminary findings from the OptiTrain trial presented at ESMO Congress.

Breast cancer survivors who participated in a remote personalized exercise program experienced modest improvements in quality of life, according to results from the eMouvoir trial presented at ESMO Congress.

A telephone-based weight loss intervention significantly increased moderate or vigorous physical activity in patients with breast cancer with overweight/obesity, according to a breast cancer weight loss trial presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

Women who breastfeed after undergoing treatment for breast cancer are not at elevated risk for recurrence or new breast cancers, two studies presented at ESMO Congress showed.

In this video, Noah Merin, MD, PhD, discusses the results of a study into the use of timdarpacept for chronic myelomonocytic leukemia, presented at ESMO Congress.

In this video, Noah Merin, MD, PhD, discusses the results of a Chinese study into the use of venetoclax in the treatment of acute myeloid leukemia and non-Hodgkin lymphoma, presented at ESMO Congress.